INSIGHT. FDA’s latest drug approvals provide clear indications of future directions in drug development and point towards more personalised and groundbreaking treatments. Here are some of the key development areas we’re seeing right now: Breakthrough in gene editing The groundbreaking approval of Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics
INSIGHT. The rapid advancement of artificial intelligence is expected to significantly transform healthcare, and implementation is gaining momentum. In a survey conducted by McKinsey earlier this year, more than 70% of participants, consisting of representatives from various healthcare organisations, indicated that they have either already implemented or are in the
NEWS. When Sciety was founded in 2014, the vision was clear – to bridge the gap between scientific breakthroughs and societal benefit. Ten years later, we have grown to become one of the Nordic region’s leading investors in life science and digital health, with over one billion SEK invested in
INSIGHT. In the pharmaceutical industry, contract development and manufacturing organizations (CDMOs) have taken on an increasingly central role. Over the past decade, these companies have shifted from being mere manufacturing partners to becoming drivers of innovation and technological development. To meet the changing demands of the pharmaceutical industry and the
At Sciety, we believe that the impact of scientific advancements should not be limited to the lab. This is why we support selected, innovative companies in life science and digital health. With deep expertise in life science, we are a long-term partner to prominent growth companies in the industry. Sciety
NEWS. Sciety supports innovative companies in life science and digital health. We help them grow and become successful, so that scientific breakthroughs in medicine and technology can become available to people all over the world. During the fall we continued our journey towards this goal, together with our portfolio companies.